• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Xueyi,SUN Pingping,SUN Chunmeng,TU Jiasheng.Research progress of Clopidogrel Injections[J].Journal Of Pharmaceutical Research,2022,41(1):37-41[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2906times   Download 2790次 QR Code for this article
Scan with your phone!
氯吡格雷注射剂的研究进展
王雪怡,孙平平,孙春萌,涂家生
Font:Larger+|Default|Smaller-
(中国药科大学药学院药剂系,国家药品监督管理局药物制剂及辅料研究与评价重点实验室,中国药科大学药用辅料及仿创药物研发评价中心,江苏 南京 210009)
摘要:
急性冠脉综合征(acute coronary syndrome, ACS)患者通常需接受经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)。手术前一般给予患者氯吡格雷以发挥抗血小板功能,但由于目前市场中仅存在氯吡格雷片,而口服起效时间较长,易于错失临床最佳治疗时机。因此,研制氯吡格雷注射剂型具有重要意义,不仅可以为急性冠脉综合征患者治疗提供一种更灵活、有效的用药选择,还可以提高急诊经皮冠状动脉介入治疗手术的成功率,降低患者血栓发生率和死亡风险。本文综述了近年来氯吡格雷注射剂的研发进展,重点讨论了相关注射剂型的技术特点和应用前景,为氯吡格雷注射剂的研发提供参考。
关键词:  氯吡格雷  抗血小板  注射剂  急性冠脉综合征  经皮冠状动脉介入治疗
DOI:10.13506/j.cnki.jpr.2022.01.007
基金项目:国家自然科学基金项目(面上项目、重点项目、重大项目)(No.81972894、81673364)
Publication Date:January 25, 2022
Research progress of Clopidogrel Injections
WANG Xueyi,SUN Pingping,SUN Chunmeng,TU Jiasheng
(NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, and Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China)
Abstract:
Patients suffering acute coronary syndrome (ACS) usually need to receive percutaneous coronary intervention (PCI). Clopidogrel is generally given to patients before operation to exert antiplatelet function. However, there is only clopidogrel tablet in the market at present, and the onset time is too long so that it is easy to miss the optimum therapeutic time. Therefore, it is urgent to develop an injectable clopidogrel formulation for clinical application. Once marketed, it can not only provide a more flexible and effective option for patients with ACS, but also improve the success rate of emergency PCI and reduce the incidence of thrombosis and the risk of death. In this review, we will introduce the progress of clopidogrel injections, briefly discuss their technical features, and provide references for the research and development of clopidogrel injections.
Key words:  Clopidogrel  Antiplatelet  Injection  ACS  PCI
Today's Visits:468    Total Visits:2383167
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.